Humulin Insulins®: Transitioning to Novolin Insulins®

Detailed information

Lilly has conducted no clinical studies evaluating the safety and efficacy of transitioning patients with either T1DM or T2DM from Novolin to Humulin or vice versa.

Changes that may affect glycemic control and predispose patients to hypoglycemia or hyperglycemia include changes in

• insulin

• manufacturer

• type, or

• method of administration. ^1-4

Any change of insulin should be made cautiously and only under medical supervision. The frequency of BG monitoring should be increased. ^1-5

Some patients taking Humulin may require a change in dosage from that used with other insulins. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.³

Enclosed Prescribing Information

HUMULIN® 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin]), injectable suspension, for subcutaneous use, Lilly

HUMULIN® N (human insulin [rDNA origin] isophane suspension), injectable suspension, for subcutaneous use, Lilly

HUMULIN® R U-100 (insulin human injection), for subcutaneous or intravenous use, Lilly

HUMULIN® R U-500 (insulin human injection), for subcutaneous use, Lilly

References

1. Humulin 70/30 [patient package insert]. Indianapolis, IN: Eli Lilly and Company; 2017.

2. Humulin N [patient package insert]. Indianapolis, IN: Eli Lilly and Company; 2017.

3. Humulin R U-100 [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018.

4. Humulin R U-500 [patient package insert]. Indianapolis, IN: Eli Lilly and Company; 2016.

5. Novolin R [package insert]. Princeton, NJ: Novo Nordisk Pharmaceuticals, Inc.; 2013.

Glossary

Lilly = Eli Lilly and Company

T1DM = type 1 diabetes mellitus

T2DM = type 2 diabetes mellitus